TCPG
AMPH icon

Trivant Custom Portfolio Group’s Amphastar Pharmaceuticals AMPH Stock Holding History

Trivant Custom Portfolio Group’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200
Closed -$8K – 174
2024
Q2 		$8K Hold
200
– – ﹤0.01% 160
2024
Q1 		$8.78K Hold
200
– – 0.01% 161
2023
Q4 		$12.4K Buy
+200
New +$10.5K 0.01% 163

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Trivant Custom Portfolio Group's AMPH Position: Q3 2024 in Review

Trivant Custom Portfolio Group sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2024, closing a stake of 200 shares — an estimated $8K sold.

Trivant Custom Portfolio Group first reported a position in AMPH in Q4 2023 and held it in 3 quarters. The position peaked at $12.4K in Q4 2023. 279 funds tracked by Wall St. Rank hold AMPH as of Q3 2024.

  • Trivant Custom Portfolio Group reported no remaining Amphastar Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Trivant Custom Portfolio Group sold 200 Amphastar Pharmaceuticals shares in Q3 2024, an estimated $8K.
  • Trivant Custom Portfolio Group first reported a position in Amphastar Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Trivant Custom Portfolio Group's Amphastar Pharmaceuticals position peaked at $12.4K in Q4 2023.
  • 279 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2024.

Based on Trivant Custom Portfolio Group's 13F filing for Q3 2024, filed 4 Oct 2024.